liraglutide
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metabolism and Nutrition Disorder
Conditions
Metabolism and Nutrition Disorder, Obesity
Trial Timeline
Aug 1, 2014 → Sep 1, 2014
NCT ID
NCT02207348About liraglutide
liraglutide is a phase 1 stage product being developed by Novo Nordisk for Metabolism and Nutrition Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT02207348. Target conditions include Metabolism and Nutrition Disorder, Obesity.
What happened to similar drugs?
5 of 20 similar drugs in Metabolism and Nutrition Disorder were approved
Approved (5) Terminated (2) Active (15)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06283641 | Pre-clinical | Completed |
| NCT05438186 | Pre-clinical | Withdrawn |
| NCT03888157 | Pre-clinical | Completed |
| NCT03560336 | Pre-clinical | Completed |
| NCT03479762 | Pre-clinical | Completed |
| NCT02967757 | Pre-clinical | Completed |
| NCT02505334 | Phase 3 | Completed |
| NCT02472717 | Phase 2 | Withdrawn |
| NCT02255266 | Pre-clinical | Completed |
| NCT02321878 | Pre-clinical | Completed |
| NCT02207348 | Phase 1 | Completed |
| NCT01821846 | Pre-clinical | Completed |
| NCT01890993 | Pre-clinical | Completed |
| NCT01499108 | Approved | Completed |
| NCT01542242 | Approved | Terminated |
| NCT01345734 | Pre-clinical | Completed |
| NCT01394341 | Approved | Completed |
| NCT01403025 | Pre-clinical | Completed |
| NCT01288326 | Pre-clinical | Completed |
| NCT01212133 | Pre-clinical | Completed |
Competing Products
20 competing products in Metabolism and Nutrition Disorder